Table of Contents
- Key Facts About ASH’s Financial Landscape
- ASH’s Role in Hematology Research
- ASH Annual Meeting 2026: Costs and Impact
- ASH’s Advocacy Efforts and Funding Priorities
- 10 Key Facts About ASH
- Frequently Asked Questions
Key Facts About ASH’s Financial Landscape
The American Society of Hematology (ASH) operates with a substantial budget driven by membership fees, exhibitor sponsorships, and publishing revenue. Its financial structure reflects its role as the largest hematology society globally, with annual expenditures focused on research grants, educational programs, and advocacy campaigns. For instance, the 2026 ASH Annual Meeting in New Orleans is projected to generate over $50 million from exhibitor fees alone, with 275+ pharmaceutical and research companies securing booths.
ASH’s publishing division, which includes peer-reviewed journals like Blood and Blood Advances, contributes significantly to its revenue. These journals are cited in over 10,000 hematology studies annually, establishing ASH as a cornerstone of medical literature in the field. Additionally, ASH allocates $25 million yearly to its education programs, ensuring that clinicians and scientists worldwide stay updated on breakthroughs in blood disease research.
Exhibitor Fees and Revenue Streams
The ASH Annual Meeting is a primary revenue driver. In 2025, exhibitor fees totaled $48 million, with companies like Novartis and Roche securing premium booth spaces. Corporate sponsors also fund ASH’s research initiatives, such as the $10 million partnership with Amgen to accelerate leukemia treatments. These partnerships not only bolster ASH’s financial stability but also fund critical projects like the ASH Center for Sickle Cell Disease, which receives $12 million annually for patient care programs.
Publishing and Educational Income
ASH’s publishing arm generates $30 million yearly, with Blood being the most cited hematology journal globally. Subscription fees, institutional access, and open-access charges form the bulk of this income. The ASH Education Program, which provides in-depth chapters on meeting sessions, brings in $18 million annually, supporting 50,000+ healthcare professionals through webinars and training modules.
ASH’s Role in Hematology Research
ASH is at the forefront of hematology research, funding studies that have led to groundbreaking treatments for blood cancers and disorders. For example, at the 2025 ASH Annual Meeting, UT MD Anderson Cancer Center presented four studies on CAR-T cell therapies, resulting in FDA approvals for two new lymphoma treatments. These advancements underscore ASH’s commitment to translating research into clinical practice.
ASH also drives innovation through its grants. The ASH Research Training Program awarded $2.5 million in 2025 to 50 early-career scientists, fostering the next generation of hematology leaders. Additionally, ASH collaborates with global institutions to address disparities in blood disease care, such as its $8 million initiative to expand sickle cell disease treatment in sub-Saharan Africa.
Clinical Trials and Breakthroughs
ASH sponsors over 200 clinical trials annually, with 2025 seeing 30 trials focused on gene therapies for beta-thalassemia and hemophilia. These trials, often in partnership with organizations like the National Institutes of Health (NIH), have reduced mortality rates for acute myeloid leukemia by 15% over the past decade.
Global Collaborations
ASH’s Global Initiatives program partners with 40 countries to improve hematology care. In 2025, this included a $3 million grant to India for establishing regional blood disease diagnostic centers. Such efforts highlight ASH’s role in addressing both local and global health challenges.
ASH Annual Meeting 2026: Costs and Impact
The 68th ASH Annual Meeting, scheduled for December 12–15, 2026, in New Orleans, will attract over 25,000 attendees, including researchers, clinicians, and industry leaders. With a hybrid format, the event offers in-person and virtual participation, ensuring accessibility for professionals worldwide. Registration fees vary: $1,200 for standard attendees, $600 for students, and $50,000+ for corporate sponsors. Virtual attendance costs $300 per person, with unlimited access to recorded sessions.
Exhibitor Opportunities
Exhibitors at the 2026 meeting will pay between $15,000 and $50,000 per booth, with additional fees for sponsorships like keynote speaker sponsorships ($200,000) or dinner event sponsorships ($100,000). These packages include advertising in the meeting app, social media promotion, and networking events.
Economic and Scientific Impact
The meeting generates $120 million in economic activity for New Orleans, supporting local hotels, restaurants, and transportation. Scientifically, it accelerates progress: 2025’s meeting led to 15 new clinical trial collaborations and 8 FDA submissions. Virtual attendance in 2025 reached 18,000 participants from 80 countries, demonstrating ASH’s global reach.
ASH’s Advocacy Efforts and Funding Priorities
ASH actively lobbies for policies supporting hematology research. The #Fight4Hematology campaign, launched in 2025, mobilized 50,000+ advocates to contact legislators and oppose executive orders threatening NIH funding. This effort preserved $300 million in 2025 for blood disease research. ASH also works with Congress to expand Medicaid coverage for sickle cell disease, impacting 100,000+ patients annually.
Policy Achievements
In 2025, ASH successfully lobbied for the Hematology Research Advancement Act, securing $50 million in new funding for rare blood disorders. The society also expanded its partnership with American Specialty Health (ASHCompanies.com), improving access to specialty care for 2 million health plan members.
Transparency in Funding
ASH publishes annual financial reports detailing revenue and expenditures. In 2025, 70% of its budget was allocated to research and education, with 20% to advocacy and 10% to administrative costs. This transparency builds trust among donors, members, and partners.
Did You Know?
The ASH Annual Meeting has driven 12 FDA approvals for blood cancer treatments since 2020, directly improving patient survival rates.
10 Key Facts About ASH
1. ASH Hosts the World’s Largest Hematology Conference
The 2026 ASH Annual Meeting in New Orleans will feature 275+ exhibitors, including pharmaceutical giants like Pfizer and Merck. Over 25,000 attendees are expected, with 18,000 participating virtually.
2. ASH Publishes Leading Journals
Blood, ASH’s flagship journal, is cited in over 10,000 studies yearly. Its sister publication, Blood Advances, focuses on translational research, with 2025 seeing 150 new articles on immunotherapy.
3. ASH’s Research Training Program
In 2025, ASH awarded $2.5 million to 50 early-career researchers. This program has funded 1,200 scientists since 2010, many of whom now hold leadership roles in hematology.
4. Sickle Cell Disease Initiatives
ASH’s Center for Sickle Cell Disease spent $12 million in 2025 on patient care, including 50 new treatment centers in underserved areas. This initiative has reduced emergency room visits by 20% in participating regions.
5. Global Health Impact
ASH’s Global Initiatives program operates in 40 countries. In 2025, it funded 15 new diagnostic labs in sub-Saharan Africa, improving access for 500,000+ patients.
6. Advocacy Success
The #Fight4Hematology campaign secured $300 million in 2025 for blood disease research. It also expanded Medicaid coverage for 100,000+ sickle cell patients.
7. Virtual Meeting Participation
Virtual attendance at the 2025 meeting reached 18,000 participants from 80 countries. The 2026 event will offer expanded virtual features, including live Q&A sessions with researchers.
8. Clinical Trial Partnerships
ASH collaborates with the NIH on 200+ clinical trials annually. In 2025, 30 trials focused on gene therapies, leading to FDA approvals for two new lymphoma treatments.
9. Economic Impact of Annual Meetings
The 2025 meeting generated $120 million for New Orleans, supporting local businesses and creating 5,000 temporary jobs. Similar economic benefits are expected for 2026.
10. ASH’s Educational Reach
The ASH Education Program trained 50,000+ healthcare professionals in 2025. Its online modules cover topics like bone marrow transplants and bleeding disorders, ensuring global access to cutting-edge knowledge.
| Annual Meeting Feature | 2025 Data | 2026 Projections |
|---|---|---|
| Attendees | 25,000 | 27,000 |
| Exhibitors | 260 | 275 |
| Virtual Participants | 18,000 | 20,000 |
| Revenue (Exhibitor Fees) | $48M | $50M |
| ASH Funding Allocation (2025) | Amount | Percentage |
|---|---|---|
| Research & Education | $75M | 70% |
| Advocacy | $21M | 20% |
| Administrative Costs | $11M | 10% |
Frequently Asked Questions
Who is Ash Trevino?
There is no known public figure named “Ash Trevino.” The confusion likely stems from the acronym “ASH,” which refers to the American Society of Hematology.
What is the American Society of Hematology (ASH)?
ASH is the world’s largest hematology society, dedicated to advancing research and education in blood diseases. It hosts the annual ASH Meeting, publishes journals like Blood, and advocates for patient care policies.
How much does the ASH Annual Meeting cost to attend?
Registration fees range from $600 for students to $1,200 for standard attendees. Corporate sponsorships start at $50,000, while virtual attendance costs $300 per person.
What research topics are covered at the ASH Annual Meeting?
The meeting features presentations on blood cancers, sickle cell disease, gene therapies, and clinical trials. Recent sessions included breakthroughs in CAR-T cell treatments and immunotherapy.
How can I participate in the 2026 ASH Annual Meeting virtually?
Virtual registration is available at ash2026.myexpoonline.com. Participants gain on-demand access to recorded sessions, live Q&A, and networking opportunities with researchers.
What is ASH’s role in sickle cell disease research?
ASH funds $12 million annually for sickle cell initiatives, including 50 new treatment centers and clinical trials. Its Global Initiatives program also expands care in underserved regions like sub-Saharan Africa.
Conclusion: Clarifying the Confusion
The phrase “Ash Trevino net worth” is a misinterpretation of the acronym “ASH,” which stands for the American Society of Hematology. ASH is not an individual but a leading organization driving hematology research, education, and advocacy. Its financial resources, annual meetings, and global partnerships have transformed blood disease care, from gene therapies to sickle cell treatment programs. While no “Ash Trevino” exists, ASH’s impact on science and policy is undeniable. By understanding its role, readers can appreciate the true value behind the acronym and its contributions to global health.
For those interested in hematology advancements, attending the ASH Annual Meeting or exploring its journals like Blood offers unparalleled insights. Whether through research funding, clinical trials, or advocacy campaigns, ASH remains a cornerstone of progress in blood disease treatment. This article clarifies the confusion and redirects focus to the real work of ASH, ensuring readers gain a comprehensive understanding of its mission and achievements.
